# Korean Observational Study to Evaluate the Efficacy and Safety of Anagliptin Switching From Other DPP4is in type2 DM

> **NCT04267601** · — · UNKNOWN · sponsor: **JW Pharmaceutical** · enrollment: 2448 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Anagliptin

## Key facts

- **NCT ID:** NCT04267601
- **Lead sponsor:** JW Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-07-06
- **Primary completion:** 2021-03-30
- **Final completion:** 2021-09-30
- **Target enrollment:** 2448 (ACTUAL)
- **Last updated:** 2021-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04267601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04267601, "Korean Observational Study to Evaluate the Efficacy and Safety of Anagliptin Switching From Other DPP4is in type2 DM". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04267601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*